Stockscreener 앱 받기
15.15
5.25%
-0.84
시간 외 거래:
15.30
0.15
+0.99%
전일 마감가:
$15.99
열려 있는:
$16.04
하루 거래량:
1.27M
Relative Volume:
1.18
시가총액:
$1.94B
수익:
-
순이익/손실:
-
주가수익비율:
-7.0289
EPS:
-2.1554
순현금흐름:
-
1주 성능:
-11.61%
1개월 성능:
-25.66%
6개월 성능:
+28.06%
1년 성능:
+0.00%
1일 변동 폭
$15.03
$16.09
1주일 범위
$15.03
$17.97
52주 변동 폭
$11.00
$22.67
Generate Biomedicines Inc Stock (GENB) Company Profile
명칭
Generate Biomedicines Inc
전화
888-469-0055
주소
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
15.15 | 1.94B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | H.C. Wainwright | Buy |
| 2026-03-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-24 | 개시 | Goldman | Buy |
| 2026-03-24 | 개시 | Guggenheim | Buy |
| 2026-03-24 | 개시 | Morgan Stanley | Overweight |
| 2026-03-24 | 개시 | Piper Sandler | Overweight |
모두보기
Generate Biomedicines Inc 주식(GENB)의 최신 뉴스
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines at Bernstein healthcare forum: data, not models By Investing.com - Investing.com Canada
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to S&P Global BMI Index - marketscreener.com
Generate Biomedicines Q2 2026 Earnings: Narrower-Than-Feared Loss Fails to Mask EPS Miss as Stock Rallies 5.93%Product Revenue Analysis - careplusvn.com
Generate Biomedicines (GENB) Slips 3.15% as Shares Test Support Near $15Max Pain Level - dars.gov.et
Generate Biomedicines at H.C. Wainwright: platform bets take center stage By Investing.com - Investing.com Canada
Generate Biomedicines at H.C. Wainwright: platform bets take center stage - Investing.com
Generate Biomedicines at Morgan Stanley conference: AI pipeline grows By Investing.com - Investing.com UK
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Generate Biomedicines at Cantor healthcare conference: pipeline gains traction By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com Australia
Generate Biomedicines (GENB) Slips 3% as Shares Test Key Support at $15.11Imbalance Zone - dars.gov.et
Generate Biomedicines to Present at Upcoming Investor Conferences - Quiver Quantitative
Five September talks will stream online from Generate Biomedicines - Stock Titan
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program - BioSpace
Director at Generate Biomedicines (GENB) sells 1,000 shares near $16 - Stock Titan
Frances Arnold plans 2026 stock sale in Generate Biomedicines (NASDAQ: GENB) - Stock Titan
Director at Generate Biomedicines (GENB) lines up a major stock sale - Stock Titan
Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data - Investing.com UK
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Generate Biomedicines discloses early respiratory drug data after congress poster leak - Endpoints News
Companies Like Generate Biomedicines (NASDAQ:GENB) Are In A Position To Invest In Growth - simplywall.st
Nvidia GPUs Are Table Stakes in AI Drug Discovery, Generate Biomedicines CTO Says - finance.biggo.com
Generate Biomedicines Reports Premature Release of GB-0895 Clinical Posters Ahead of ERS Congress 2026 - Kalkine Media
Generate Biomedicines Stock Slides 20% as 103 Million Shares Clear Lock-Up - TechStock²
Certain Warrants of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Generate Biomedicines shares jump 20% ahead of post-IPO lock-up expiry - Pluang
Nvidia backs Generate Biomedicines in AI drug discovery push - scanx.trade
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Shares Up 4.9%Still a Buy? - MarketBeat
8 Stocks Nvidia Has Invested In - U.S. News Money
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business ... - Caledonian Record
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView
Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView
Generate Biomedicines Inc (GENB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):